文献速递肿瘤 PET/CT核素与放射性配体治疗

GPC3:肝细胞癌的新型诊疗一体化靶点

Glypican-3: Novel Theranostic Agent for Hepatocellular Carcinoma.
PubMed 文献 · Semin Nucl Med · 2025-09-26

本文综述了靶向磷脂酰肌醇蛋白聚糖3(GPC3)的PET显像与放射性核素治疗研究进展。显像从89Zr/124I标记完整抗体发展为18F/68Ga标记小分子支架以实现同日高对比显像,早期人体研究证实肿瘤特异性摄取;治疗涵盖β和α发射体,在模型中显示抗肿瘤活性但存在剂量与毒性问题。

要点

  • GPC3在多数肝细胞癌高表达而正常成人肝低表达,是诊疗一体化理想靶点。
  • 小分子支架(F(ab')₂、单域抗体、多肽)配18F/68Ga可实现同日高对比PET显像。
  • α发射体(225Ac、227Th)治疗需关注剂量学与毒性,尤其是长循环抗体载体。

核心结论

  • GPC3靶向诊疗一体化是肝细胞癌精准管理的潜力路径,但需解决安全性及定量显像缺口。

研究设计与样本

  • 综述汇总GPC3靶向PET显像与放射性核素治疗的临床前及早期临床研究。

主要发现

  • 89Zr/124I标记完整抗体显示稳健但延迟的肿瘤定位,18F/68Ga标记小支架可实现同日高对比显像。
  • 124I-codrituzumab和68Ga-RAYZ-8009首次人体研究证实肿瘤特异性摄取但规模有限。
  • 90Y、177Lu及225Ac、227Th在原位和异种移植模型中显示强效抗肿瘤作用,但存在剂量与毒性担忧。

临床怎么用

  • 优先选择有限先导载体与合适核素配对,在原位/PDX模型中以标准化终点验证。
  • 进入广泛人体试验前需整合全面剂量学与毒理学研究。

局限性

  • 早期人体研究规模有限。
  • 肝背景清除、患者内GPC3表达异质性、大动物毒理及核素供应物流仍是转化挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Glypican-3 (GPC3) is a membrane-anchored heparan sulfate proteoglycan overexpressed in many hepatocellular carcinomas (HCCs) while minimally present in normal adult liver, making it an attractive target for integrated diagnostic and therapeutic ("theranostic") strategies. This review synthesizes preclinical and early clinical efforts to exploit GPC3 for targeted PET imaging and radionuclide therapy. Imaging approaches have evolved from 89Zr- and 124I-labeled full antibodies-demonstrating robust, delayed tumor localization-to smaller scaffolds (F(ab')₂, single-domain antibodies, peptides) paired with 18F or 68Ga for same-day, high-contrast imaging. First-in-human studies, including 124I-codrituzumab and 68Ga-RAYZ-8009, confirmed tumor-specific accumulation but remained limited in scale. Therapeutic investigations spanned beta-emitters (90Y, 177Lu) and high-LET alpha-emitters (225Ac, 227Th), showing potent antitumor effects in orthotopic and xenograft models yet raising dosimetric and toxicity concerns-especially for long-circulating antibody carriers and alpha therapies. Key translational challenges include hepatic background clearance, intra-patient heterogeneity of GPC3 expression, rigorous dosimetry, toxicology in larger species, and radionuclide supply logistics. The available evidence suggests a preferential pathway, involving the selection of a limited set of lead vectors, their pairing with suitable radionuclides, validation in orthotopic/PDX models using standardized endpoints, and the integration of comprehensive dosimetric and toxicologic studies before proceeding to broader human trials. GPC3-directed theranostics thus offers a compelling, disease-specific route to precision management of HCC, provided translational rigor addresses the outlined safety and quantitative imaging gaps.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Filippi L. Glypican-3: Novel Theranostic Agent for Hepatocellular Carcinoma. Semin Nucl Med. 2025. PMID: 41015658. doi:10.1053/j.semnuclmed.2025.09.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。